Mesoblast Stock Analysis
MESO Stock | USD 15.62 3.28 26.58% |
Mesoblast is undervalued with Real Value of 18.13 and Target Price of 27.0. The main objective of Mesoblast stock analysis is to determine its intrinsic value, which is an estimate of what Mesoblast is worth, separate from its market price. There are two main types of Mesoblast's stock analysis: fundamental analysis and technical analysis.
The Mesoblast stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Mesoblast is usually not traded on Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day. Mesoblast Stock trading window is adjusted to America/New York timezone.
Mesoblast | Build AI portfolio with Mesoblast Stock |
Mesoblast Stock Analysis Notes
The book value of the company was now reported as 0.4. The company recorded a loss per share of 1.28. Mesoblast had not issued any dividends in recent years. The entity had 1:2 split on the 10th of January 2024. Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia. Mesoblast operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 77 people. To find out more about Mesoblast contact FACP FACRA at 61 3 9639 6036 or learn more at https://www.mesoblast.com.Mesoblast Quarterly Total Revenue |
|
Mesoblast Investment Alerts
Mesoblast is way too risky over 90 days horizon | |
Mesoblast appears to be risky and price may revert if volatility continues | |
The company reported the previous year's revenue of 5.9 M. Net Loss for the year was (87.96 M) with loss before overhead, payroll, taxes, and interest of (20.99 M). | |
Mesoblast currently holds about 85.5 M in cash with (48.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.62. | |
Mesoblast has a poor financial position based on the latest SEC disclosures | |
Latest headline from gurufocus.com: Jefferies Adjusts Mesoblast Rating and Price Target Post Q4 Report MESO Stock News |
Mesoblast Upcoming and Recent Events
Earnings reports are used by Mesoblast to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
26th of February 2024 Upcoming Quarterly Report | View | |
23rd of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
4th of September 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
30th of June 2023 Last Financial Announcement | View |
Mesoblast Largest EPS Surprises
Earnings surprises can significantly impact Mesoblast's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2023-02-27 | 2022-12-31 | -0.1802 | -0.1574 | 0.0228 | 12 | ||
2022-05-31 | 2022-03-31 | -0.13 | -0.16 | -0.03 | 23 | ||
2020-05-27 | 2020-03-31 | -0.17 | -0.14 | 0.03 | 17 |
Mesoblast Environmental, Social, and Governance (ESG) Scores
Mesoblast's ESG score is a quantitative measure that evaluates Mesoblast's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Mesoblast's operations that may have significant financial implications and affect Mesoblast's stock price as well as guide investors towards more socially responsible investments.
Mesoblast Thematic Classifications
In addition to having Mesoblast stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
![]() | Cancer FightersPublic companies from health care and pharmaceutical sectors that are focused on fighting cancer | |
![]() | Pharmaceutical ProductsUSA Equities from Pharmaceutical Products industry as classified by Fama & French |
Mesoblast Stock Institutional Investors
Shares | Marshall Wace Asset Management Ltd | 2025-03-31 | 71.7 K | Rockbridge Investment Management, Llc | 2025-03-31 | 49.1 K | Prosperity Wealth Management Inc | 2025-03-31 | 48.7 K | Jane Street Group Llc | 2025-03-31 | 48.6 K | Oasis Management Co. Ltd | 2025-03-31 | 41.5 K | Lpl Financial Corp | 2025-03-31 | 40 K | Bank Of America Corp | 2025-03-31 | 36.6 K | Xy Capital Ltd | 2025-03-31 | 27.8 K | Wells Fargo & Co | 2025-03-31 | 26.6 K | Blackrock Inc | 2025-03-31 | 714.9 K | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 544.6 K |
Mesoblast Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 2 B.Management Efficiency
Mesoblast has return on total asset (ROA) of (0.0485) % which means that it has lost $0.0485 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2131) %, meaning that it created substantial loss on money invested by shareholders. Mesoblast's management efficiency ratios could be used to measure how well Mesoblast manages its routine affairs as well as how well it operates its assets and liabilities.Leadership at Mesoblast emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Technical Drivers
As of the 20th of July, Mesoblast secures the Mean Deviation of 3.51, downside deviation of 4.12, and Risk Adjusted Performance of 0.1324. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Mesoblast, as well as the relationship between them.Mesoblast Price Movement Analysis
The output start index for this execution was thirteen with a total number of output elements of fourty-eight. The Simple Moving Average indicator is calculated by adding the closing price of Mesoblast for a given number of time periods and then dividing this total by the number of time periods. It is used to smooth out Mesoblast short-term fluctuations and highlight longer-term trends or cycles.
Mesoblast Outstanding Bonds
Mesoblast issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Mesoblast uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Mesoblast bonds can be classified according to their maturity, which is the date when Mesoblast has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Mesoblast Predictive Daily Indicators
Mesoblast intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Mesoblast stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Mesoblast Corporate Filings
6K | 18th of July 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 15th of July 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 1st of July 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 12th of June 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 15th of May 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 30th of April 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 29th of April 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 24th of April 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
Mesoblast Forecast Models
Mesoblast's time-series forecasting models are one of many Mesoblast's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Mesoblast's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Mesoblast Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Mesoblast prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Mesoblast shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Mesoblast. By using and applying Mesoblast Stock analysis, traders can create a robust methodology for identifying Mesoblast entry and exit points for their positions.
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia. Mesoblast operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 77 people.
Current Mesoblast Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Mesoblast analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Mesoblast analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
27.0 | Strong Buy | 3 | Odds |
Most Mesoblast analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Mesoblast stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Mesoblast, talking to its executives and customers, or listening to Mesoblast conference calls.
Mesoblast Stock Analysis Indicators
Mesoblast stock analysis indicators help investors evaluate how Mesoblast stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Mesoblast shares will generate the highest return on investment. By understating and applying Mesoblast stock analysis, traders can identify Mesoblast position entry and exit signals to maximize returns.
Begin Period Cash Flow | 71.3 M | |
Long Term Debt | 100.5 M | |
Common Stock Shares Outstanding | 98.7 M | |
Total Stockholder Equity | 480.4 M | |
Total Cashflows From Investing Activities | -97 K | |
Tax Provision | -191 K | |
Property Plant And Equipment Net | 3.8 M | |
Cash And Short Term Investments | 62.6 M | |
Cash | 62.6 M | |
Accounts Payable | 7.1 M | |
Net Debt | 56.4 M | |
50 Day M A | 11.2246 | |
Total Current Liabilities | 73.2 M | |
Other Operating Expenses | 90 M | |
Non Current Assets Total | 582.7 M | |
Forward Price Earnings | 454.5455 | |
Non Currrent Assets Other | 2.1 M | |
Stock Based Compensation | 5.9 M |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mesoblast. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mesoblast. If investors know Mesoblast will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mesoblast listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.28) | Revenue Per Share 0.05 | Quarterly Revenue Growth (0.07) | Return On Assets (0.05) | Return On Equity |
The market value of Mesoblast is measured differently than its book value, which is the value of Mesoblast that is recorded on the company's balance sheet. Investors also form their own opinion of Mesoblast's value that differs from its market value or its book value, called intrinsic value, which is Mesoblast's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mesoblast's market value can be influenced by many factors that don't directly affect Mesoblast's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mesoblast's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mesoblast is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mesoblast's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.